News >

Sandoz Enters Licensing Agreement for Trastuzumab Biosimilar

Gina Columbus @ginacolumbusonc
Published: Tuesday, Apr 30, 2019

Stefan Hendriks

Stefan Hendriks

Sandoz has entered into an agreement with EirGenix, Inc., to commercialize the proposed trastuzumab (Herceptin) biosimilar EG12014 for use as a treatment of patients with HER2-positive breast and select gastric cancers.1

In the double-blind, parallel group, 3-arm phase I trial (EGC001; NCT03180242), investigators evaluated the pharmacokinetic similarity between the biosimilar and trastuzumab in 84 healthy male patients.

References

  1. Sandoz Enters Agreement for Proposed Trastuzumab Biosimilar, Currently in Phase III Development, to Treat Selected HER2-Positive Cancer Tumors. Novartis. Published April 30, 2019. https://bit.ly/2XWwayU. Accessed April 30, 2019.
  2. EirGenix Scores Phase I Success For Its Leading Biosimilar Product EG12014. EirGenix. Published May 4, 2017. https://bit.ly/2IQTYRk. Accessed April 30, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Addressing Uncertainties in Oncology BiosimilarsApr 30, 20201.5
Community Practice Connections™: Show Me the Data™: Leveraging the Evidence to Optimize Applications of Biosimilars in CancerAug 30, 20201.5
Publication Bottom Border
Border Publication
x